Head-To-Head Review: Palatin Technologies (PTN) and Bio-Path Holdings (BPTH)

Palatin Technologies (NYSE: PTN) and Bio-Path Holdings (NASDAQ:BPTH) are both large-cap biotechnology & medical research – nec companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Palatin Technologies has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Bio-Path Holdings has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500.


This table compares Palatin Technologies and Bio-Path Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Palatin Technologies 39.28% N/A 90.43%
Bio-Path Holdings N/A -56.53% -43.24%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Palatin Technologies and Bio-Path Holdings, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palatin Technologies 0 0 2 0 3.00
Bio-Path Holdings 0 0 2 0 3.00

Palatin Technologies presently has a consensus target price of $4.00, indicating a potential upside of 441.27%. Bio-Path Holdings has a consensus target price of $3.50, indicating a potential upside of 993.75%. Given Bio-Path Holdings’ higher probable upside, analysts plainly believe Bio-Path Holdings is more favorable than Palatin Technologies.

Earnings and Valuation

This table compares Palatin Technologies and Bio-Path Holdings’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Palatin Technologies N/A N/A N/A ($0.09) -8.21
Bio-Path Holdings $10,000.00 3,201.92 -$6.75 million ($0.07) -4.57

Palatin Technologies has higher revenue, but lower earnings than Bio-Path Holdings. Palatin Technologies is trading at a lower price-to-earnings ratio than Bio-Path Holdings, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.2% of Bio-Path Holdings shares are held by institutional investors. 12.5% of Bio-Path Holdings shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Bio-Path Holdings beats Palatin Technologies on 6 of the 9 factors compared between the two stocks.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.

About Bio-Path Holdings

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

What are top analysts saying about Palatin Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Palatin Technologies Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit